Reply to letter to editor "Cancer patients should be considered as a high-risk priority target in the COVID-19 vaccination process"

J Surg Oncol. 2021 Sep;124(3):455. doi: 10.1002/jso.26507. Epub 2021 Apr 20.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Neoplasms*
  • SARS-CoV-2
  • Vaccination

Substances

  • COVID-19 Vaccines